The Type 1 Angiotensin II Receptor pipeline drugs market research report outlays comprehensive information on the Type 1 Angiotensin II Receptor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Type 1 Angiotensin II Receptor pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.

Smarter leaders trust GlobalData

The report also covers products from therapy areas such as Cardiovascular, Metabolic Disorders, Genito Urinary System, and Central Nervous System which include the indications Idiopathic (Essential) Hypertension, Hypertension, Dyslipidemia, Hyperlipidemia, Chronic Kidney Disease (Chronic Renal Failure), Focal Segmental Glomerulosclerosis (FSGS), Traumatic Brain Injury, and Insomnia. It also reviews key players involved in Type 1 Angiotensin II Receptor targeted therapeutics development with respective active and dormant or discontinued products.

The Type 1 Angiotensin II Receptor pipeline targets constitutes close to 45 molecules. Out of which, approximately 42 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/ CTA Filed, and Preclinical stages are 5, 15, 5, 7, 1, and 9 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 2, and 1 molecule.

Type 1 Angiotensin II Receptor overview

Angiotensin II receptor type 1 (AT1R) is a G protein-coupled receptor (GPCR) that plays a crucial role in the renin-angiotensin system (RAS), a complex hormonal pathway that regulates blood pressure, fluid balance, and electrolyte homeostasis. AT1R is the primary mediator of the biological actions of angiotensin II (Ang II), a potent vasoconstrictor and proinflammatory peptide.

For a complete picture of Type 1 Angiotensin II Receptor’s drug pipeline, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.